- Now that its new lab is open in Edmonton, Canada, Gilead is seeking to hire up to 170 scientists.
- Gilead is also at work on a second Edmonton-based lab, which will be used to manufacture API, as well as for maintenance and upgrades.
- This growth, which is intended to facilitate Gilead's pipeline expansion, is driven by huge Sovaldi (sofosbuvir) revenues, which exceeded $10 billion in 2014.
Gilead's growth trajectory is strong---and especially in Edmonton, which is where the company sourced its clinical trial supplies for HCV, HIV and new cancer therapies at an existing facility. Between January 2014 and January 2015, Gilead's overall workforce grew from roughly 6,100 to 7,000 fulltime employees---and that growth trend is continuing. The new lab in Edmonton is expected to open within a week.